Blood eosinophilia: A new paradigm in disease classification, diagnosis, and treatment

Mayo Clinic Proceedings

Volumn 80, Issue 1, 2005, Pages 75-83

  Tefferi, Ayalew ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BCR ABL PROTEIN; CLADRIBINE; CORTICOSTEROID; CYCLOSPORIN; ETOPOSIDE; HYDROXYUREA; IMATINIB; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; VINCRISTINE;

ACUTE LEUKEMIA; ALGORITHM; ALLERGY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PREFERENCE; DRUG TARGETING; DRUG USE; EOSINOPHIL; EOSINOPHILIA; EVALUATION; FAMILIAL EOSINOPHILIA; GENE INACTIVATION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HISTOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFLAMMATION; LEUKOCYTE COUNT; LOW DRUG DOSE; NEOPLASM; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PARASITOSIS; PATHOGENICITY; PRIMARY EOSINOPHILIA; RECEPTOR GENE; REVIEW; SECONDARY EOSINOPHILIA; SPECIES INVASION; TREATMENT FAILURE;

EID: 11344249990     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)62962-5     Document Type: Review

References (160)

1. Denburg JA, Telizyn S, Messner H, et al. Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophileosinophil progenitor. Blood. 1985;66:312-318.
2. Rothenberg ME, Eosinophilia. N Engl J Med. 1998;338:1592-1600.
3. Yamaguchi Y, Hayashi Y, Sugama Y, et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival: IL-5 as an eosinophil chemotactic factor. J Exp Med. 1988;167:1737-1742.
4. Elsner J, Kapp A. The chemokine network in eosinophil activation. Allergy Asthma Proc. 2001;22:139-148.
5. Dobrina A, Menegazzi R, Carlos TM, et al. Mechanisms of eosinophil adherence to cultured vascular endothelial cells: eosinophils bind to the cytokine-induced ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. J Clin Invest. 1991;88:20-26.
6. Gleich GJ, Adolphson CR, Leiferman KM. The biology of the eosinophilic leukocyte. Annu Rev Med. 1993;44:85-101.
7. Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, Barker RL. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol. 1990;144:3166-3173.
8. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol. 1989;142:4428-4434.
9. Torpier G, Colombel JF, Mathieu-Chandelier C, et al. Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol. 1988;74:404-408.
10. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987;1:643-647.
11. Slifman NR, Loegering DA, McKean DJ, Gleich GJ. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil canonic protein. J Immunol. 1986;137:2913-2917.
12. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986;321:613-616.
13. Sorrentino S, Glitz DG, Hamann KJ, Loegering DA, Checkel JL, Gleich GJ. Eosinophil-derived neurotoxin and human liver ribonuclease: identity of structure and linkage of neurotoxicity to nuclease activity. J Biol Chem. 1992;267:14859-14865.
14. Sunohara N, Furukawa S, Nishio T, Mukoyama M, Satoyoshi E. Neurotoxicity of human eosinophils towards peripheral nerves. J Neural Sci. 1989;92:1-7.
15. Chen KR, Su WP, Pittelkow MR, Conn DL, George T, Leiferman KM. Eosinophilic vasculitis in connective tissue disease. J Am Acad Dermatol. 1996;35(2,pt 1):173-182.
16. Shah AM, Brutsaert DL, Meulemans AL, Andries LJ, Capron M. Eosinophils from hypereosinophilic patients damage endocardium of isolated feline heart muscle preparations. Circulation. 1990;81:1081-1088.
17. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol. 2003;121:203-223.
18. Lin AY, Nutman TB, Kaslow D, et al. Familial eosinophilia: clinical and laboratory results on a U.S. kindred. Am J Med Genet. 1998;76:229-237.
19. Yakulis R, Bedetti CD. Loffler's endocarditis: occurrence with malignant lymphoma with a high content of epithelioid histiocytes ('Lennert's lymphoma'). Arch Pathol Lab Med. 1983;107:531-534.
20. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1-27.
21. Bakhshi S, Hamre M, Mohamed AN, Feldman G, Ravindranath Y. t(5;9)(q11;q34): a novel familial translocation involving Abelson oncogene and association with hypereosinophilia. J Pediatr Hematol Oncol. 2003;25:82-84.
22. Rioux JD, Stone VA, Daly MJ, et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet. 1998;63:1086-1094.
23. Baxter EJ, Kulkarni S, Vizmanos J-L, et al. Novel translocations that disrupt the platelet-derived growth factor receptor β (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol. 2003;120:251-256.
24. Klion AD, Law MA, Riemenschneider W, et al. Familial eosinophilia: a benign disorder? Blood. 2004;103:4050-4055.
25. Evengard B. Diagnostic and clinical aspects of schistosomiasis in 182 patients treated at a Swedish ward for tropical diseases during a 10-year period. Scand J Infect Dis. 1990;22:585-594.
26. Zinkham WH. Visceral larva migrans: a review and reassessment indicating two forms of clinical expression: visceral and ocular. Am J Dis Child. 1978;132:627-633.
27. Milder JE, Walzer PD, Kilgore G, Rutherford I, Klein M. Clinical features of Strongyloides stercoralis infection in an endemic area of the United States. Gastroenterology. 1981;80:1481-1488.
28. Hussain R, Hamilton RG, Kumaraswami V, Adkinson NF Jr, Ottesen EA. IgE responses in human filariasis, I: quantitation of filaria-specific IgE. J Immunol. 1981;127:1623-1629.
29. Maxwell C, Hussain R, Nutman TB, et al. The clinical and immunologic responses of normal human volunteers to low dose hookworm (Necator americanus) infection. Am J Trop Med Hyg. 1987;37:126-134.
30. Arjona R, Riancho JA, Aguado JM, Salesa R, Gonzalez-Macias J. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore). 1995;74:13-23.
31. Pozio E, Varese P, Morales MA, Croppo GP, Pelliccia D, Bruschi F. Comparison of human trichinellosis caused by Trichinella spiralis and by Trichinella britovi. Am J Trop Med Hyg. 1993;48:568-575.
32. Uchiyama F, Morimoto Y, Nawa Y. Re-emergence of paragonimiasis in Kyushu, Japan. Southeast Asian J Trop Med Public Health. 1999;30:686-691.
33. Windsor JJ, Johnson EH. Dientamoeba fragilis: the unflagellated human flagellate. Br J Biomed Sci. 1999;56:293-306.
34. Grant SC, Klein C. Toxoplasma gondii encephalitis in an immunocompetent adult: a case report. S Afr Med J. 1987;71:585-587.
35. Junod C. Isospora belli coccidiosis in immunocompetent subjects (a study of 40 cases seen in Paris) [in French]. Bull Soc Pathol Exot Filiales. 1988;81:317-325.
36. Granter SR, Barnhill RL, Duray PH. Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am J Dermatopathol. 1996;18:465-473.
37. Tietz A, Sponagel L, Erb P, Bucher H, Battegay M, Zimmerli W. Eosinophilia in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis. 1997;16:675-677.
38. Spry CJ. Eosinophilia and allergic reactions to drugs. Clin Haematol. 1980;9:521-534.
39. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology. 2003;206:353-356.
40. Ichiche M, Kiesch N, De Bels D. DRESS syndrome associated with HHV-6 reactivation. Eur J Intern Med. 2003;14:498-500.
41. De Marco P, Melchiori G. Carbamazepine and eosinophilia [letter]. Ann Neurol. 1986;20:274.
42. Gonzales-Chambers R, Rosenfeld C, Winkelstein A, Dameshek L. Eosinophilia resulting from administration of recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in a patient with T-gamma lymphoproliferative disease. Am J Hematol. 1991;36:157-159.
43. Seebach J, Speich R, Fehr J, Tuchschmid P, Russi E. GM-CSF-induced acute eosinophilic pneumonia. Br J Haematol. 1995;90:963-965.
44. Trojan A, Meier R, Licht A, Taverna C. Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma. Ann Hematol. 2002;81:535-537.
45. Yamakado S, Yoshida Y, Yamada T, Kishida T, Kobayashi M, Nomura T. Pulmonary infiltration and eosinophilia associated with sulfasalazine therapy for ulcerative colitis: a case report and review of literature. Intern Med. 1992;31:108-113.
46. Clauw DJ, Nashel DJ, Umhau A, Katz P. Tryptophan-associated eosinophilic connective-tissue disease: a new clinical entity? JAMA. 1990;263:1502-1506.
47. Kilbourne EM, Posada de la Paz M, Abaitua Borda I, Diez Ruiz-Navarro M, Philen RM, Falk H. Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome. J Am Coll Cardiol. 1991;18:711-717.
48. Mert A, Tabak F, Aktuglu Y. Eosinophilia in toxic shock syndrome: review of 20 cases [letter]. Scand J Infect Dis. 1998;30:320.
49. Griffin E, Hakansson L, Formgren H, Jorgensen K, Peterson C, Venge P. Blood eosinophil number and activity in relation to lung function in patients with asthma and with eosinophilia. J Allergy Clin Immunol. 1991;87:548-557.
50. Uehara M, Izukura R, Sawai T. Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol. 1990;15:264-266.
51. Chapman BJ, Capewell S, Gibson R, Greening AP, Crompton GK. Pulmonary eosinophilia with and without allergic bronchopulmonary aspergulosis. Thorax. 1989;44:919-924.
52. Desenne JJ, Acquatella G, Stern R, Muller A, Sanchez M, Somoza R. Blood eosinophilia in Hodgkin's disease: a follow-up of 25 cases in Venezuela. Cancer. 1992;69:1248-1253.
53. Scales JW, McMichael A. Persistent peripheral eosinophilia and cutaneous non-Hodgkin's lymphoma: a case report and review of the literature. Cutis. 2001;67:67-70.
54. Watanabe K, Shinbo T, Kojima M, Naito M, Tanahashi N, Nara M. B-cell lymphoma associated with eosinophilia. Cancer. 1989;64:1682-1685.
55. Navarro-Roman L, Medeiros LJ, Kingma DW, et al. Malignant lymphomas of B-cell lineage with marked tissue eosinophilia: a report of five cases. Am J Surg Pathol. 1994;18:347-356.
56. Fridlender ZG, Simon HU, Shalit M. Metastatic carcinoma presenting with concomitant eosinophilia and thromboembolism. Am J Med Sci. 2003;326:98-101.
57. Walter R, Joller-Jemelka HI, Salomon F. Metastatic squamous cell carcinoma with marked blood eosinophilia and elevated serum interleukin-5 levels [letter]. Exp Hematol. 2002;30:1-2.
58. Spry C. Eosinophilia in Addison's disease. Yale J Biol Med. 1976;49:411-413.
59. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996;2:449-456.
60. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood. 1999;93:2463-2470.
61. Balducci L, Chapman SW, Little DD, Hardy CL. Paraneoplastic eosinophilia: report of a case with in vitro studies of hemopoiesis. Cancer. 1989; 64:2250-2253.
62. Sanada I, Asou N, Kojima S, Kawano F, Shido T, Takatsuki K. Acute myelogenous leukemia (FAB M1) associated with t(5;16) and eosinophilia: report of an additional case. Cancer Genet Cytogenet. 1989;43:139-141.
63. Blatt PM, Rothstein G, Miller HL, Cathey WJ. Loffler's endomyocardial fibrosis with eosinophilia in association with acute lymphoblastic leukemia. Blood. 1974;44:489-493.
64. Keung YK, Beaty M, Steward W, Jackle B, Pettnati M. Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet. 2002;138:139-142.
65. Kuroda J, Kimura S, Akaogi T, et al. Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration. Acta Haematol. 2000;104:119-123.
66. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003;102:4187-4190.
67. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol. 2003;122:173-179.
68. Ma SK, Kwong YL, Shek TW, et al. The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Hum Pathol. 1999;30:864-868.
69. Yam LT, Yam CF, Li CY. Eosinophilia in systemic mastocytosis. Am J Clin Pathol. 1980;73:48-54.
70. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French-Arnerican-British Cooperative Leukaemia Group. Br J Haematol. 1994;87:746-754.
71. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
72. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038-3045.
73. Elliott MA, Pardanani A, Li CY, Tefferi A. Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis [letter]. Leukemia. 2004;18:1027-1029.
74. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093-3096.
75. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
76. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 2002;11:1391-1397.
77. Miranda RN, Esparza AR, Sambandam S, Medeiros LJ. Systemic mast cell disease presenting with peripheral blood eosinophilia. Hum Pathol. 1994;25:727-730.
78. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473-478.
79. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18:734-742.
80. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with it(5;12) chromosomal translocation. Cell. 1994;77:307-316.
81. Granjo E, Lima M, Lopes JM, et al. Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical; immunological and cytogenetic features and therapeutic approach: a case report. Acta Haematol. 2002;107:108-112.
82. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
83. Gupta R, Knight CL, Bain BJ. Receptor tyrosine kinase mutations in myeloid neoplasms. Br J Haematol. 2002;117:489-508.
84. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107:101-107.
85. Sohal J, Chase A, Mould S, et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer. 2001;32:155-163.
86. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations [NIH conference]. Ann Intern Med. 1982;97:78-92.
87. Liesveld JL, Abboud CN. State of the art: the hypereosinophilic syndromes. Blood Rev. 1991;5:29-37.
88. Lin DA, Boyce JA. The idiopathic hypereosinophilic syndrome. Allergy Asthma Proc. 2003;24:417-420.
89. Owen J, Scott JG. Transition of the hypereosinophilic syndrome to myelomonocytic leukemia. Can Med Assoc J. 1979;121:1489-1491.
90. Yoo TJ, Orman SV, Patil SR, et al. Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome. Cancer Genet Cytogenet. 1984;11:389-394.
91. Needleman SW, Mane SM, Gutheil JC, Kapil V, Heyman MR, Testa JR. Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol. 1990;4:149-155.
92. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651-1657.
93. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000;109:540-548.
94. Raghavachar A, Fleischer S, Frickhofen N, Heimpel H, Fleischer B. T lymphocyte control of human eosinophilic granulopoiesis: clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol. 1987;139:3753-3758.
95. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341:1112-1120.
96. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med. 1983;52:1-22.
97. Kazmierowski JA, Chusid MJ, Parrillo JE, Fauci AS, Wolff SM. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol. 1978;114:531-535.
98. Leiferman KM, O'Duffy JD, Perry HO, Greipp PR, Giuliani ER, Gleich GJ. Recurrent incapacitating mucosal ulcerations: a prodrome of the hypereosinophilic syndrome. JAMA. 1982;247:1018-1020.
99. Bogenrieder T, Griese DP, Schiffner R, et al. Wells' syndrome associated with idiopathic hypereosinophilic syndrome. Br J Dermatol. 1997;137:978-982.
100. Parrillo JE, Borer JS, Henry WL, Wolff SM, Fauci AS. The cardiovascular manifestations of the hypereosinophilic syndrome: prospective study of 26 patients, with review of the literature. Am J Med. 1979;67:572-582.
101. Sato Y, Taniguchi R, Yamada T, et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder [letter]. Intern Med. 2000;39:350.
102. Dorfman LJ, Ransom BR, Forno LS, Kelts A. Neuropathy in the hypereosinophilic syndrome. Muscle Nerve. 1983;6:291-298.
103. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1985;102:109-114.
104. Weingarten JS, O'Sheal SF, Margolis WS. Eosinophilic meningitis and the hypereosinophilic syndrome: case report and review of the literature. Am J Med. 1985;78:674-676.
105. Tsai CP, Yeh HH, Tsai JJ, Lin KP, Wu ZA. Transverse myelitis and polyneuropathy in idiopathic hypereosinophilic syndrome [letter]. Muscle Nerve. 1993;16:112-113.
106. Slabbynck H, Impens N, Naegels S, Dewaele M, Schandevyl W. Idiopathic hypereosinophilic syndrome-related pulmonary involvement diagnosed by bronchoalveolar lavage. Chest. 1992;101:1178-1180.
107. Winn RE, Kollef MH, Meyer JI. Pulmonary involvement in the hypereosinophilic syndrome. Chest. 1994;105:656-660.
108. Kang EY, Shim JJ, Kim JS, Kim KI. Pulmonary involvement of idiopathic hypereosinophilic syndrome: CT findings in five patients. J Comput Assist Tomogr. 1997;21:612-615.
109. Scheurlen M, Mork H, Weber P. Hypereosinophilic syndrome resembling chronic inflammatory bowel disease with primary sclerosing cholangitis. J Clin Gastroenterol. 1992;14:59-63.
110. Catalano L, Pastena S, Catalano M, Lestini A, Valentini G, Rotoli B. Eosinophilic gastroenteritis: a rare localization of the hypereosinophilic syndrome? [letter]. Haematologica. 1992;77:292-293.
111. Grauer L, Padilla VM III, Bouza L, Barkin JS. Eosinophilic sclerosing cholangitis associated with hypereosinophilic syndrome. Am J Gastroenterol. 1993;88:1764-1769.
112. Ichikawa N, Taniguchi A, Akama H, et al. Sclerosing cholangitis associated with hypereosinophilic syndrome. Intern Med. 1997;36:561-564.
113. Elouaer-Blanc L, Zafrani ES, Farcet JP, Saint-Marc Girardin MF, Mathieu D, Dhumeaux D. Hepatic vein obstruction in idiopathic hypereosinophilic syndrome. Arch Intern Med. 1985;145:751-753.
114. Vargas CA, Maldonado O, Botero RC, et al. Budd-Chiari syndrome associated with the hypereosinophilic syndrome [letter]. Am J Gastroenterol. 1993;88:1802-1803.
115. Chaine G, Davies J, Kohner EM, Hawarth S, Spry CJ. Ophthalmologic abnormalities in the hypereosinophilic syndrome. Ophthalmology. 1982;89:1348-1356.
116. Peison B, Benisch B, Lim M, Chin JC. Idiopathic hypereosinophilic syndrome with polymyositis. South Med J. 1988;81:403-406.
117. Bulucu F, Can C, Inal V, Baykal Y, Erikci S. Renal involvement in a patient with idiopathic hypereosinophilic syndrome [letter]. Clin Nephrol. 2002;57:171-173.
118. Prattichizzo FA, Bernini L. An idiopathic hypereosinophilic syndrome mimicking seronegative rheumatoid arthritis: 20-year follow-up with clinical and laboratory findings. Clin Exp Rheumatol. 1992;10:79-81.
119. Appelbaum FR. Molecular diagnosis and clinical decisions in adult acute leukemia. Semin Hematol. 1999;36:401-410.
120. O'Brien SG, Guilhot F, Larson RA, et al, IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
121. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
122. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Ab1 protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
123. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
124. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
125. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
126. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938-1942.
127. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol. 2004;11:58-64.
128. Takeuchi K, Koike K, Kamijo T, et al. STI571 inhibits growth and adhesion of human mast cells in culture. J Leukoc Biol. 2003;74:1026-1034.
129. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31:686-692.
130. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 2003;22:660-664.
131. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535-536.
132. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103:3960-3963.
133. Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-α positive idiopathic hypereosinophilic syndrome [letter]. Haematologica. 2004;89:236-237.
134. Frickhofen N, Marker-Hermann E, Reiter A, et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol. 2004;83:477-480.
135. Rose C, Dupire S, Roche-Lestienne C, et al. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft [letter]. Leukemia. 2004;18:354-355.
136. Pitini V, Arrigo C, Teti D, Barresi G, Righi M, Alo G. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report. Haematologica. 2003;88:ECR18.
137. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167-172.
138. Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome, II: clinical manifestations. Blood. 1981;58:1021-1026.
139. Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol. 1991;62:230-231.
140. Sakamoto K, Erdreich-Epstein A, deClerck Y, Coates T. Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol. 1992;14:348-351.
141. Marshall GM, White L. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol. 1989;11:178-183.
142. Fruehauf S, Fiehn C, Haas R, Doehner H, Hunstein W. Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy. Acta Haematol. 1993;89:91-93.
143. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa. J Allergy Clin Immunol. 1994;94(6,pt 2):1318-1326.
144. Ceretelli S, Capochiani E, Petrini M. Interferon-α in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol. 1998;77:161-164.
145. Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome [letter]. Leukemia. 1997;11:1386-1390.
146. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991;67:2826-2827.
147. Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:647-648.
148. Fukushima T, Kuriyama K, Ito H, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol. 1995;90:213-215.
149. Juvonen E, Volin L, Koponen A, Ruutu T. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant. 2002;29:457-458.
150. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002;119:131-134.
151. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103:2939-2941.
152. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113:115-119.
153. Plotz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334-2339.
154. Sefcick A, Sowter D, DasGupta E, Russell NH, Byrne JL. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome [letter]. Br J Haematol. 2004;124:558-559.
155. Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib [letter] . Am J Med. 2003;115:587-589.
156. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391-3397.
157. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes [letter]. Blood. 2003;102:3456-3457.
158. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-1578.
159. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
160. Tipping AJ, Baluch S, Barnes DJ, et al. Efficacy of dual-specific Bcr-Ab1 and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia. 2004;18:1352-1356.